Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 88 points (-0.5%) at 17,785 as of Tuesday, May 31, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,627 issues advancing vs. 1,333 declining with 171 unchanged.

The Health Care sector currently sits up 1.5% versus the S&P 500, which is down 0.2%. Top gainers within the sector include

Neurocrine Biosciences

(

NBIX

), up 8.1%,

Alnylam Pharmaceuticals

(

ALNY

), up 7.2%,

Vertex Pharmaceuticals

(

VRTX

), up 3.2%,

Grifols

(

GRFS

), up 2.8% and

Biogen

(

BIIB

), up 2.6%. On the negative front, top decliners within the sector include

Medtronic

(

MDT

), down 1.6%,

Edwards Lifesciences

(

EW

), down 1.2%,

Novartis

(

NVS

), down 0.9%,

Becton Dickinson

(

BDX

), down 0.9% and

Shire

(

SHPG

), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Incyte

(

INCY

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Incyte is up $1.10 (1.3%) to $85.63 on light volume. Thus far, 392,498 shares of Incyte exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $84.68-$86.20 after having opened the day at $85.00 as compared to the previous trading day's close of $84.53.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. Incyte has a market cap of $15.9 billion and is part of the drugs industry. Shares are down 22.1% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Incyte a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Incyte

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, poor profit margins and generally higher debt management risk. Get the full

Incyte Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Biomarin Pharmaceutical

(

BMRN

) is up $1.28 (1.4%) to $90.37 on average volume. Thus far, 584,025 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $89.35-$91.26 after having opened the day at $89.46 as compared to the previous trading day's close of $89.09.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $14.5 billion and is part of the drugs industry. Shares are down 15.0% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Biomarin Pharmaceutical

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Biomarin Pharmaceutical Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Mylan

(

MYL

) is up $0.40 (0.9%) to $43.46 on light volume. Thus far, 1.8 million shares of Mylan exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $42.97-$43.56 after having opened the day at $43.25 as compared to the previous trading day's close of $43.06.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $21.9 billion and is part of the drugs industry. Shares are down 20.4% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Mylan a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Mylan

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Mylan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).